BEXSERO

The actual benefit of BEXSERO is substantial in the active immunisation against invasive serogroup B meningococcal disease, but only in the populations recommended by the Haut Conseil de la Santé Publique in its opinion of 25 October 2013.

On the basis of the available data, the Committee considers that BEXSERO provides a substantial improvement in actual benefit (IAB II) in the prevention of invasive serogroup B meningococcal disease in the populations recommended by the Haut Conseil de la Santé Publique.